MNG171
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.604
- OXIDATIVE_PHOSPHORYLATION+0.572
- MYC_TARGETS_V1+0.421
- MYC_TARGETS_V2+0.385
- E2F_TARGETS+0.367
- INTERFERON_GAMMA_RESPONSE+0.358
- FATTY_ACID_METABOLISM+0.312
- G2M_CHECKPOINT+0.288
- DNA_REPAIR+0.287
- MTORC1_SIGNALING+0.267
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.452
- ANGIOGENESIS-0.385
- UV_RESPONSE_DN-0.336
- WNT_BETA_CATENIN_SIGNALING-0.335
- APICAL_JUNCTION-0.320
- HEDGEHOG_SIGNALING-0.320
- MYOGENESIS-0.300
- APICAL_SURFACE-0.298
- COAGULATION-0.267
- TGF_BETA_SIGNALING-0.263
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-55-1596-01A-01R-0946-07 | — | cohortA4 | 0.895 |
| 2 | SRR27320678 | — | — | 0.891 |
| 3 | SRR8613729 | — | E | 0.876 |
| 4 | TCGA-66-2763-01A-01R-0851-07 | — | cohortSQ1 | 0.876 |
| 5 | C3N-00580 | — | cohortA1 | 0.868 |
| 6 | MNG95 | — | — | 0.866 |
| 7 | TCGA-C8-A12U-01A-11R-A115-07 | — | B | 0.865 |
| 8 | SRR8518323 | — | E | 0.860 |
| 9 | MNG277 | — | — | 0.859 |
| 10 | SRR11296797 | — | — | 0.855 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 18 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.604 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.572 | Remibrutinib | — uncovered |
| MYC_TARGETS_V1 | 0.421 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.385 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.367 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.358 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.312 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.288 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.287 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.267 | Inavolisib | — uncovered |
| PEROXISOME | 0.193 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.171 | Remibrutinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.148 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.142 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.097 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.062 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.037 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.007 | Inavolisib | — uncovered |